Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2022
February 2022, Vol 13, No 1 Online Only
February 2022, Vol 13, No 1 Online Only
Abiraterone plus Prednisone Added to ADT Boosts Survival in Patients with High-Risk Prostate Cancer
By
Phoebe Starr
Prostate Cancer
February 2022, Vol 13, No 1 Online Only
Two years of abiraterone acetate (Zytiga) plus prednisone added to androgen-deprivation therapy (ADT) improved metastasis-free survival and overall survival compared with ADT alone in men with nonmetastatic castration-sensitive prostate cancer, whereas the addition of enzalutamide (Xtandi) to ADT had no benefit, and much greater toxicity.
Read More
Adagrasib Demonstrates Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer
By
Phoebe Starr
Colorectal Cancer
February 2022, Vol 13, No 1 Online Only
Adagrasib (MRTX849), an inhibitor of the
KRAS
G12C
mutation, showed promising activity as monotherapy and in combination with cetuximab (Erbitux) in patients with metastatic colorectal cancer (CRC) in the phase 1/2 KRYSTAL-1 trial.
Read More
mRNA COVID-19 Vaccine Appears Safe and Effective in Patients with Cancer Receiving Active Treatment
By
Chase Doyle
COVID-19
February 2022, Vol 13, No 1 Online Only
Vaccination with the mRNA-1273 vaccine (Moderna) appears safe in patients with solid tumors receiving immunotherapy, chemotherapy, or chemoimmunotherapy.
Read More
Trastuzumab Deruxtecan Promising in Patients with HER2-Positive Breast Cancer and Brain Metastases
By
Phoebe Starr
SABCS Highlights
February 2022, Vol 13, No 1 Online Only
Second-line therapy with trastuzumab deruxtecan (Enhertu; T-DXd) extended progression-free survival (PFS) and improved objective response rate (ORR) versus trastuzumab emtansine (Kadcyla; T-DM1) in women with
HER2
-positive metastatic breast cancer, including those with stable brain metastasis at baseline, according to a subgroup analysis of a phase 3 clinical trial.
Read More
KEYNOTE-355: Pembrolizumab plus Chemotherapy Extends Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
By
Phoebe Starr
SABCS Highlights
February 2022, Vol 13, No 1 Online Only
Final results from the pivotal phase 3 KEYNOTE-355 trial showed that the addition of pembrolizumab (Keytruda) to chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) compared with chemotherapy alone in patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1 with a combined positive score (CPS) ≥10.
Read More
Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma
By
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
Treatment with the investigational agent mosunetuzumab (RG7828) as monotherapy induced deep remissions in patients with relapsed/refractory follicular lymphoma, according to results of a recent trial presented at the ASH 2021 Annual Meeting and Exposition.
Read More
Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies
By
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
Results from 2 single-center studies presented at the ASH 2021 Annual Meeting and Exposition showed that nearly 1 in 6 patients with hematologic diseases had no or low antibody response after a second COVID-19 vaccination, but that the mRNA 1273 COVID-19 vaccine induced a strong antibody response in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Read More
CAR T-Cell Therapies Show Efficacy in Second-Line Treatment of Large B-Cell Lymphoma
By
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
The results from 2 phase 3 clinical trials highlighted the superiority of CAR T-cell therapies over current standard of care (SOC) when used earlier in the course of treatment for patients with large B-cell lymphoma (LBCL).
Read More
Pharmacist-Driven Intervention Leads to Significant Increase in Biosimilar Adoption
By
Chase Doyle
Biosimilars
February 2022, Vol 13, No 1 Online Only
Rapid adoption of FDA-approved biosimilars is feasible, measurable, and scalable—and pharmacists should lead the charge, according to data presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium.
Read More
Oncology Pipeline Overview: Recent Approvals and Near-Term Drugs
By
Wayne Kuznar
AVBCC 2021 Summit
February 2022, Vol 13, No 1 Online Only
Many innovative therapies in oncology have made it to market recently, with a wealth of agents that are currently on the verge of FDA approval.
Read More
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma